{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T10:29:20Z","timestamp":1776853760999,"version":"3.51.2"},"reference-count":53,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1016\/j.clinthera.2009.06.015","type":"journal-article","created":{"date-parts":[[2009,8,19]],"date-time":"2009-08-19T08:25:15Z","timestamp":1250670315000},"page":"1158-1176","source":"Crossref","is-referenced-by-count":31,"title":["Certolizumab pegol for the management of Crohn's disease in adults"],"prefix":"10.1016","volume":"31","author":[{"given":"Anastasia","family":"Rivkin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2009.06.015_bib1","series-title":"Harrison's Principles of Internal Medicine","article-title":"Inflammatory bowel disease","author":"Friedman","year":"2008"},{"key":"10.1016\/j.clinthera.2009.06.015_bib2","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/ibd.20029","article-title":"Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940\u20132000","volume":"13","author":"Loftus","year":"2007","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.clinthera.2009.06.015_bib3","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1111\/j.1572-0241.2006.00552.x","article-title":"Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003\u20132005: A population-based study from the Danish Crohn colitis database","volume":"101","author":"Vind","year":"2006","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.clinthera.2009.06.015_bib4","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0016-5085(98)70421-4","article-title":"Crohn's disease in Olmsted County, Minnesota, 1940\u20131993: Incidence, prevalence, and survival [published correction appears in Gastroenterology. 1999;116:1507]","volume":"114","author":"Loftus","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2009.06.015_bib5","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1053\/j.gastro.2004.01.063","article-title":"Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences","volume":"126","author":"Loftus","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2009.06.015_bib7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1046\/j.1365-2036.2002.01140.x","article-title":"The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: A systematic review","volume":"16","author":"Loftus","year":"2002","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.clinthera.2009.06.015_bib8","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1111\/j.1572-0241.2007.01343.x","article-title":"The immune response in inflammatory bowel disease","volume":"102","author":"Brown","year":"2007","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.clinthera.2009.06.015_bib9","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/j.1365-2036.2004.01967.x","article-title":"Mutations in the NOD2\/CARD15 gene in Crohn's disease are associated with ileocecal resection and are a risk factor for reoperation","volume":"19","author":"B\u00fcning","year":"2004","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.clinthera.2009.06.015_bib10","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0016-5085(98)70381-6","article-title":"Inflammatory bowel disease: Etiology and pathogenesis","volume":"115","author":"Fiocchi","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2009.06.015_bib11","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1572-0241.2001.03671.x","article-title":"Management of Crohn's disease in adults","volume":"96","author":"Hanauer","year":"2001","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.clinthera.2009.06.015_bib12","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ajg.2008.168","article-title":"Management of Crohn's disease in adults","volume":"104","author":"Lichtenstein","year":"2009","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.clinthera.2009.06.015_bib13","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/MOG.0b013e3281722271","article-title":"Inflammatory bowel disease diagnosis, evaluation and classification: State-of-the-art approach","volume":"23","author":"Targan","year":"2007","journal-title":"Curr Opin Gastroenterol."},{"key":"10.1016\/j.clinthera.2009.06.015_bib14","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/0016-5085(94)90398-0","article-title":"Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease","volume":"106","author":"Breese","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2009.06.015_bib15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/ibd.3780040110","article-title":"The central role of chemokines (chemotactic cytokines) in the immu-nopathogenesis of ulcerative colitis and Crohn's disease","volume":"4","author":"MacDermott","year":"1998","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.clinthera.2009.06.015_bib16","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1136\/gut.43.2.203","article-title":"Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease","volume":"43","author":"Noguchi","year":"1998","journal-title":"Gut."},{"key":"10.1016\/j.clinthera.2009.06.015_bib17","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/gut.32.8.913","article-title":"Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease","volume":"32","author":"Murch","year":"1991","journal-title":"Gut."},{"key":"10.1016\/j.clinthera.2009.06.015_bib18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0140-6736(92)90999-J","article-title":"Tumour necrosis factor alpha in stool as a marker of intestinal inflammation","volume":"339","author":"Braegger","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2009.06.015_bib19","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1053\/j.gastro.2007.05.006","article-title":"American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21\u201323, 2006","volume":"133","author":"Clark","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2009.06.015_bib20","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/art.21405","article-title":"Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeST study): A randomized, controlled trial","volume":"52","author":"Goekoop-Ruiterman","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clinthera.2009.06.015_bib21","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1053\/j.gastro.2005.05.064","article-title":"Management of recent onset Crohn's disease: A controlled, randomized trial comparing step-up and top-down therapy","volume":"129","author":"Hommes","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2009.06.015_bib22","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1053\/gast.2002.31072","article-title":"A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease","volume":"122","author":"Sandborn","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2009.06.015_bib23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00004836-199201000-00005","article-title":"Quality of life in inflammatory bowel disease","volume":"14","author":"Love","year":"1992","journal-title":"J Clin Gastroenterol."},{"key":"10.1016\/j.clinthera.2009.06.015_bib24","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0016-5085(94)90585-1","article-title":"Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease","volume":"106","author":"Irvine","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2009.06.015_bib25","first-page":"535","article-title":"A new generation of high-affinity humanized PEGylated Fab fragment antitumor necrosis factor-monoclonal antibodies","volume":"3","author":"Weir","year":"2006","journal-title":"Therapy"},{"key":"10.1016\/j.clinthera.2009.06.015_bib26","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/ibd.20225","article-title":"Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor alpha agents","volume":"13","author":"Nesbitt","year":"2007","journal-title":"Inflamm Bowel Dis."},{"issue":"Suppl","key":"10.1016\/j.clinthera.2009.06.015_bib27","doi-asserted-by":"crossref","first-page":"S299","DOI":"10.14309\/00000434-200509001-00807","article-title":"In vitro complement-dependent cytotoxicity and antibody-dependent cellular cyto-toxicity by the anti-TNF agents adalimumab, etanercept, infliximab, and certolizumab pegol (CDP870)","volume":"100","author":"Fossati","year":"2005","journal-title":"Am J Gastroenterol."},{"issue":"Suppl","key":"10.1016\/j.clinthera.2009.06.015_bib28","doi-asserted-by":"crossref","first-page":"S298","DOI":"10.14309\/00000434-200509001-00806","article-title":"Effect of the anti-TNF agents, adalimumab, etanercept, infliximab, and certolizumab pegol (CDP870) on the induction of apoptosis in activated peripheral blood lymphocytes and monocytes","volume":"100","author":"Fossati","year":"2005","journal-title":"Am J Gastroenterol."},{"issue":"Suppl","key":"10.1016\/j.clinthera.2009.06.015_bib29","doi-asserted-by":"crossref","first-page":"S437","DOI":"10.14309\/00000434-200609001-01117","article-title":"Investigation of the pharmacokinetic properties of certolizumab pegol, an anti-TNF agent","volume":"101","author":"Baker","year":"2006","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.clinthera.2009.06.015_bib30","series-title":"Cimzia (certolizumab pegol) [package insert]","year":"2008"},{"key":"10.1016\/j.clinthera.2009.06.015_bib31","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn's disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2009.06.015_bib32","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":"Maintenance therapy with certolizumab pegol for Crohn's disease [published correction appears in N Engl J Med. 2007;357:1357]","volume":"357","author":"Schreiber","year":"2007","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2009.06.015_bib33","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1053\/j.gastro.2005.06.064","article-title":"A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease [published correction appears in Gastroenterology. 2005;129:1808]","volume":"129","author":"Schreiber","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2009.06.015_bib34","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/j.1365-2036.2004.02285.x","article-title":"Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: An exploratory study","volume":"20","author":"Winter","year":"2004","journal-title":"Aliment Pharmacol Ther."},{"issue":"Suppl","key":"10.1016\/j.clinthera.2009.06.015_bib35","first-page":"A697","article-title":"Neutralization of soluble and membrane tumor necrosis factor-alpha (TNF-alpha) by infliximab, adalimumab, or certolizumab pegol using P55 or P75 TNF-alpha receptor-specific bioassays","volume":"130","author":"Gramlick","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2009.06.015_bib36","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1053\/j.gastro.2005.07.041","article-title":"C-reactive protein: Anti-placebo or predictor of response","volume":"129","author":"Lewis","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2009.06.015_bib37","series-title":"Presented at: 65th Annual Scientific Meeting of the American College of Rheumatology","article-title":"CDP870, a novel pegylated humanized TNF-alpha inhibitor, is effective in treating the signs and symptoms of rheumatoid arthritis (RA)","author":"Keystone","year":"2001"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2009.06.015_bib38","first-page":"A489","article-title":"T1129 predictors of response in patients with active Crohn's Disease treated with certolizumab pegol: A multiple regression analysis of PRECISE 2 data","volume":"134","author":"Hanauer","year":"2008","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2009.06.015_bib39","first-page":"A490","article-title":"T1133 efficacy and tolerability of certolizumab pegol are sustained over 18 months: Data from PRECISE 2 and its extension studies (PRECISE 3 and 4)","volume":"134","author":"Schreiber","year":"2008","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2009.06.015_bib40","doi-asserted-by":"crossref","first-page":"S429","DOI":"10.14309\/00000434-200809001-01099","article-title":"The long-term, 30 months, efficacy and tolerability of certolizumab pegol therapy for Crohn's Disease","volume":"103","author":"Sandborn","year":"2008","journal-title":"Am J Gastroenterol."},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2009.06.015_bib41","first-page":"S423","article-title":"Endoscopic mucosal improvement in patients with active Crohn's Disease treated with certolizumab pegol: First results of the MUSIC clinical trial","volume":"103","author":"Colombel","year":"2008","journal-title":"Am J Gastroenterol."},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2009.06.015_bib43","first-page":"A68","article-title":"Long-term safety of an anti-TNF drug by duration of exposure compared to non-anti-TNF exposed patients with Crohn's disease: Novel data from the certolizumab pegol development program","volume":"143","author":"Lichtenstein","year":"2008","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2009.06.015_bib44","doi-asserted-by":"crossref","first-page":"S430","DOI":"10.14309\/00000434-200809001-01101","article-title":"Long-term safety of certolizumab pegol in Crohn's disease: Integrated safety findings on serious adverse events of special interest","volume":"103","author":"Colombel","year":"2008","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.clinthera.2009.06.015_bib46","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2009.06.015_bib47","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2009.06.015_bib48","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2009.06.015_bib49","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2009.06.015_bib50","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: A randomized trial","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann Intern Med."},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2009.06.015_bib51","doi-asserted-by":"crossref","first-page":"S427","DOI":"10.14309\/00000434-200809001-01093","article-title":"Efficacy of intensification therapy with certolizumab pegol in Crohn's disease patients included in a compassionate-use program","volume":"103","author":"Fernandez-Blanco","year":"2008","journal-title":"Am J Gastroenterol."},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2009.06.015_bib52","doi-asserted-by":"crossref","first-page":"S429","DOI":"10.14309\/00000434-200809001-01098","article-title":"Certolizumab pegol therapy in patient with Crohn's disease with previous loss of response to 2 anti-TNF agents","volume":"103","author":"Domenech","year":"2008","journal-title":"Am J Gastroenterol."},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2009.06.015_bib53","first-page":"A67","article-title":"Efficacy and safety of certolizumab pegol in patients with active Crohn's disease who previously lost response or were intolerant to infliximab: Open-label induction preliminary results of the WELCOME study","volume":"134","author":"Vermeire","year":"2008","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2009.06.015_bib54","doi-asserted-by":"crossref","first-page":"S430","DOI":"10.14309\/00000434-200809001-01103","article-title":"Certolizumab pegol is efficacious in Crohn's disease patients who have failed infliximab regardless of concomitant therapy or reason for failure","volume":"103","author":"Abreu","year":"2008","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.clinthera.2009.06.015_bib55","series-title":"Red Book September 2008 Update","year":"2008"},{"key":"10.1016\/j.clinthera.2009.06.015_bib56","series-title":"Red Book 2008","year":"2008"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809001982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809001982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T14:42:37Z","timestamp":1590072157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291809001982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["S0149291809001982"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2009.06.015","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}